Pharmaceutical

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.

Jul 10, 2024 - 04:00
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
Read the original article

Tags:

Previous Article

Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan

Next Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Crossject secures funding from French Government for needle-free platform

Crossject secures funding from French Government for ne...

Jul 14, 2024

ProKidney amends Phase III protocol in light of Phase II results

ProKidney amends Phase III protocol in light of Phase I...

Nov 14, 2023

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT+: Pharmalittle: Woodcock to retire from the FDA; A...

Nov 17, 2023